The research, led by Faezeh Khorasanizadeh of the Department of Radiology at Razi Hospital, Tehran University of Medical Sciences, together with colleagues in dermatology, epidemiology, and biostatistics, and in collaboration with Ximena Wortsman of the Universidad de Chile, a pioneer in cutaneous ultrasound, enrolled eighteen patients with newly biopsy-confirmed morphea. Every participant had at least one clinically active plaque at baseline. The investigators deliberately designed the protocol to be practical: rather than imaging every lesion, they selected the most clinically probable active plaque in each patient and compared it with adjacent or contralateral normal skin serving as an internal control. Each patient then underwent grayscale ultrasound, color Doppler ultrasound, and shear-wave elastography at the start of the study and again after six months of treatment, alongside standardized clinical scoring. The study received ethical approval from the institutional review board of Tehran University of Medical Sciences and was conducted in accordance with the Declaration of Helsinki, with written informed consent obtained from all participants and guardians of minors.

The technical logic behind the imaging approach is worth unpacking. High-frequency grayscale ultrasound can resolve the individual layers of the skin with millimeter precision, allowing radiologists to measure dermal thickness, the hallmark of fibrotic thickening in morphea, and hypodermal thickness, which reflects the fat layer beneath. In active lesions, inflammation and edema typically thicken the dermis and can alter the echotexture of the subcutis. Color Doppler ultrasound adds a functional dimension by detecting blood flow; increased vascularity within and beneath a plaque is considered a marker of subclinical inflammatory activity that may persist even when the skin surface appears quiescent. Shear-wave elastography, the most technically sophisticated of the three, works by generating shear waves, a form of transverse mechanical vibration, within the tissue and measuring the speed at which they propagate. Because stiffer tissue transmits shear waves faster than soft tissue, the technique yields a quantitative estimate of tissue elasticity in kilopascals, turning the subjective sensation of hardened skin into a reproducible number.

After six months of follow-up, the results told a clear and clinically meaningful story. Dermal thickness, measured ultrasonographically, decreased significantly alongside a significant fall in mean clinical scores, with p values below 0.05. The LoSAI activity score dropped from a mean of 4.28 plus or minus 3.28 at baseline to 1.44 plus or minus 1.75 after treatment, while the LoSDI damage score declined from 11.39 plus or minus 7.38 to 9.56 plus or minus 6.77. Hypodermal thickness also decreased and skin elasticity increased slightly over the six months, but neither of these secondary changes reached statistical significance. The pattern makes biological sense: inflammation-driven dermal thickening responds to immunosuppressive therapy within months, whereas fibrotic remodeling of the subcutis and restoration of elastic properties are slower processes that may lag behind clinical improvement or, in the case of established damage, never fully reverse.

Perhaps the most intriguing findings emerged from the correlation analyses. Hypodermal thickness correlated negatively with the Physician Global Assessment of Damage, with a Spearman rho of -0.410 and a p value of 0.027, and positively with the LoSAI activity index, with rho of 0.513 and p of 0.004. Hypodermal thickness was also positively correlated with the Physician Global Assessment of Activity before treatment began. After therapy, hypodermal stiffness measured by elastography correlated positively with the LoSDI damage index. Taken together, these relationships suggest that the subcutaneous fat layer, often overlooked in favor of the dermis, carries real diagnostic information: a thicker hypodermis tracks with active disease, while stiffer subcutaneous tissue tracks with accumulated damage. This positions elastography not merely as a research curiosity but as a potential bridge between the activity and damage domains that clinicians must distinguish when deciding whether to escalate, continue, or taper therapy.

Not every result favored the new technology, and the authors were candid about the limitations. When radiologists and dermatologists independently rated disease activity using shear-wave elastography and color Doppler, the inter-rater agreement was poor, with a kappa of just 0.053, barely above chance. This discordance likely reflects the steep learning curve of cutaneous ultrasound, differences in probe positioning and pressure, and the absence of universally standardized scoring protocols across specialties. It is a sobering reminder that a measurement technique is only as objective as the protocol governing its use. The authors also emphasized that their cohort was small, with only eighteen patients, all of whom had plaque-type or linear morphea, the most common subtypes. Generalizing to rarer variants such as generalized, deep, or pansclerotic morphea will require larger and more diverse cohorts, and the six-month follow-up window may be too short to capture slower changes in elasticity and subcutaneous architecture.

Why does an objective biomarker matter so much for morphea specifically? Current treatment typically involves systemic corticosteroids combined with methotrexate or, increasingly, other immunomodulators, a regimen that carries real toxicity and demands months of commitment. Because clinical scores are subjective and damage can masquerade as activity, physicians risk both overtreating patients whose disease has already burned out and undertreating those with smoldering subclinical inflammation that continues to cause irreversible fibrosis. Ultrasound-based measures could change this calculus in several ways: by providing early, quantitative evidence of response within weeks rather than months; by identifying subclinical activity that warrants continued therapy even when the skin looks better; and by serving as surrogate endpoints in clinical trials, where the rarity of morphea has long made adequately powered studies difficult. Prior work by Wortsman and colleagues on the Ultrasound Morphea Activity Scoring system, and by other groups applying shear-wave elastography in both localized and systemic scleroderma, has laid the groundwork, but this study is among the first to track patients longitudinally through treatment with a multimodal protocol.

The study also fits into a broader movement in dermatology toward quantitative, imaging-based assessment of skin disease. Thermal imaging has been explored for detecting inflammation in localized scleroderma, dermoscopy offers clues to disease stage, and 50-megahertz ultrasound has documented improvement after ultraviolet A1 phototherapy. In systemic sclerosis, elastography is being evaluated as a measure of skin strain and fibrosis severity, raising the possibility of a shared imaging vocabulary across the sclerosing diseases. A recent consensus statement on the diagnosis and treatment of sclerosing skin diseases underscores how much remains unsettled in monitoring these conditions, and the authors of the current study position their work as a preliminary but prospective step toward filling that gap with tools that are already available in most radiology departments.

For now, the take-home message is measured but promising. In this preliminary prospective cohort, dermal thickness measured with high-frequency ultrasound emerged as the strongest candidate for an objective marker of treatment response in morphea, while color Doppler and shear-wave elastography showed potential as adjunctive tools whose clinical utility remains exploratory. The authors themselves stress that validation in larger cohorts is essential before these techniques enter routine practice, and the poor inter-rater agreement highlights the need for standardized acquisition and scoring protocols, ideally with dedicated training for both radiologists and dermatologists. Still, the direction of travel is unmistakable. If subsequent studies confirm these findings, the era of guessing whether a morphea plaque is truly quiet could give way to an era in which a handheld probe, a quantitative elasticity map, and a few millimeters of measured dermis tell clinicians exactly what the immune system is doing beneath the skin, and whether the treatment they have chosen is actually working.

Subject of Research: Ultrasound and shear-wave elastography for monitoring treatment response in morphea

Article Title: Ultrasound and shear-wave elastography as a tool for evaluating response to treatment of morphea: a preliminary report of a prospective study

Article References: Khorasanizadeh, F., Sharifi, M. A., Vahabi, S. M., Ansari, M. S., Ghandi, N., Hosseini, F., Etesami, I., & Wortsman, X. (2026). Ultrasound and shear-wave elastography as a tool for evaluating response to treatment of morphea: a preliminary report of a prospective study. Archives of Dermatological Research, 318(1), Article 457. https://doi.org/10.1007/s00403-026-04919-7

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04919-7

Keywords: morphea, localized scleroderma, ultrasound, shear-wave elastography, color Doppler, dermal thickness, LoSAI, LoSDI, treatment response, biomarkers, dermatology, skin fibrosis

The motivation comes from a growing recognition that skin diseases are not uniform across depth. Using spatial transcriptomics, the research team mapped bleomycin-induced fibrotic skin and found sharply stratified pathology. In the subcutaneous layer, the adipocyte marker Fabp4 progressively declined, reflecting fat loss and metabolic dysfunction. In the dermis, the senescence marker Cdkn1a steadily rose, pointing to an accumulation of aged, inflammation-secreting fibroblasts. Histological examination of clinical specimens from patients with localized scleroderma confirmed the same architecture: disorganized dermal collagen and fibrotic replacement of the subdermal adipose compartment. Immunofluorescence co-staining revealed senescent fibroblasts clustered in the dermis and adipocyte-to-myofibroblast transition, known as AMT, in the subcutis.

These findings suggest that the dermis and subcutis follow separate pathogenic programs, with the dermis driven by inflammation and cellular senescence and the fat layer driven by metabolic failure and fibrotic remodeling. Conventional delivery approaches cannot respect that geography. Subcutaneous injections and electroporation tend to leave mRNA stranded in the superficial dermis, while standard microneedle patches struggle to reach beyond the upper skin compartments. The stratum corneum, the skin’s tough outer barrier, remains a formidable obstacle for nucleic acid therapeutics, and controlling delivery depth has been an persistent challenge in cutaneous mRNA medicine.

The new platform builds on the team’s earlier threaded microneedle technology, in which continuous spiral grooves are etched into a stainless-steel needle roughly 4 millimeters long with an outer diameter of 230 micrometers. The grooves serve as protective channels that guide nanoformulated cargo along the insertion tract, reducing shear stress and tissue damage while enabling layer-resolved deposition. In prior work, the platform delivered neurotrophic factors for nerve repair and penetrated cartilage’s subchondral region for joint repair. For the skin application, the distal 1.5 millimeters of the threaded region carries the therapeutic payload.

The two therapeutic modules were engineered with complementary release behaviors. The first is SRT1720@HA, a hyaluronic acid hydrogel loaded with SRT1720, a SIRT1 agonist chosen after spatial transcriptomic analysis identified SIRT1 as a target in the epidermal and superficial dermal regions. Rheological testing confirmed a stable viscoelastic network, and in vitro release experiments showed roughly 80 percent cumulative SRT1720 release over 96 hours. The second module is PGC1α@LNP, lipid nanoparticles encapsulating messenger RNA encoding PGC-1α, a master regulator of mitochondrial metabolism identified as a target in the dermal-subcutaneous transitional zone. The nanoparticles measured about 108 nanometers in diameter, achieved an encapsulation efficiency of 92.6 percent, and released approximately 65 percent of their mRNA payload over 96 hours. Confocal imaging demonstrated time-dependent endosomal escape, and the formulation survived lyophilization and one month of storage without losing its ability to drive PGC1α expression in cells.

When the two modules were combined on a single threaded needle, fluorescence tracing in simulated skin and in living mice revealed a striking spatial division of labor. The hydrogel coating, sitting on the needle’s exterior, was preferentially wiped off during insertion and retained in the dermis, much like a conventional coated needle. The groove-embedded nanoparticles, protected from premature displacement, were carried along the full insertion tract and deposited from the dermis into the subcutaneous layer, particularly during rotational manipulation. Each microneedle carried roughly 44 nanograms of encapsulated PGC1α mRNA and about 15 nanograms of SRT1720, quantified by batch weighing and liquid chromatography-tandem mass spectrometry.

Safety and localization data supported the design. CCK-8 assays, EdU proliferation tests, and live-dead staining showed that both carriers were well tolerated by L929 fibroblasts and differentiated 3T3-L1 adipocytes across the tested concentration ranges. After microneedle application, exogenous PGC1α mRNA was detected only in treated dorsal skin, declining over time, while SRT1720 remained below the limit of quantification in plasma, lymph nodes, liver, and spleen. The system delivered its payloads locally with no measurable systemic exposure.

In cell models, each module addressed its layer-specific pathology. In senescent fibroblasts, SRT1720@HA reduced β-galactosidase positivity, restored migratory capacity in scratch assays, and dampened expression of senescence markers CDKN2A and CDKN1A along with SASP cytokines including IL-6 and IL-1β. In an AMT model where TGF-β1 pushed adipocytes toward a myofibroblast-like state, PGC1α@LNP preserved lipid droplets, upregulated adipocyte genes such as PPARγ, Perilipin, and Adiponectin, and downregulated fibrotic markers including α-SMA and Col1a1 at both the RNA and protein levels.

The decisive test came in bleomycin-induced skin fibrosis mice treated every other day for two weeks. All microneedle-based interventions improved fibrotic features, but the dual-loaded system performed best, markedly reducing dermal thickness, collagen deposition, and elastic fiber destruction. Layer-specific mechanisms were confirmed by immunostaining: the hydrogel module cut the proportion of senescent dermal fibroblasts, while the nanoparticle module suppressed AMT in the subcutaneous fat, and only the combination achieved both. Transcriptomic sequencing showed that combined treatment silenced p53 signaling, inflammatory genes, and matrix-remodeling pathways while reactivating lipid biosynthesis, mitochondrial electron transport, and PPAR-dependent metabolic programs.

The authors caution that the mouse model does not fully recapitulate human fibrosis, that dose-matched free-drug controls are still needed to separate cargo effects from the platform itself, and that long-term durability and recurrence after treatment cessation remain open questions. Even so, the study demonstrates a versatile blueprint for layer-specific intervention in skin disease, one that could extend beyond fibrosis to any condition whose pathology is written differently in the dermis than in the fat beneath it.

Subject of Research: Layer-specific dermal and subcutaneous drug and mRNA delivery using a modular LNP-hydrogel threaded microneedle platform for treating skin fibrosis

Article Title: Layer‐Specific Dermal and Subcutaneous Delivery via Modular LNP–Hydrogel‐Integrated Threaded Microneedles

Article References: Xie, F., Zhang, Y., Ling, S., Huang, Y., Wei, Y., Fu, R., He, J., Liu, B., Zhou, L., Huo, K., Wang, Y., Li, Q., Du, Y., Cui, W., & Xie, Y. (2026). Layer‐Specific Dermal and Subcutaneous Delivery via Modular LNP–Hydrogel‐Integrated Threaded Microneedles. Advanced Science, Article e77624. https://doi.org/10.1002/advs.77624

Image Credits: AI Generated

DOI: 10.1002/advs.77624

Keywords: microneedles, mRNA therapy, lipid nanoparticles, skin fibrosis, spatial transcriptomics, SIRT1, PGC-1α, hydrogel, senescence, adipocyte-to-myofibroblast transition, drug delivery, Advanced Science